BIOLOGICAL · Unmapped registry intervention
Ramucirumab
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer
NCT01256567
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Docetaxel
Normalized identity: docetaxelView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Metastatic Breast Cancerunresolved
Interventions
RamucirumabBIOLOGICAL
DocetaxelDRUG · verified · RxNorm: docetaxel
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01256567 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.